Gene Expression Profiles in BCL11B-siRNA Treated Malignant T Cells

Xin Huang,Qi Shen,Si Chen,Shaohua Chen,Lijian Yang,Jianyu Weng,Xin Du,Piotr Grabarczyk,Grzegorz K Przybylski,Christian A Schmidt,Yangqiu Li
DOI: https://doi.org/10.1186/1756-8722-4-23
IF: 28.5
2011-01-01
Journal of Hematology & Oncology
Abstract:Background Downregulation of the B-cell chronic lymphocytic leukemia (CLL)/lymphoma11B ( BCL11B) gene by small interfering RNA (siRNA) leads to growth inhibition and apoptosis of the human T-cell acute lymphoblastic leukemia (T-ALL) cell line Molt-4. To further characterize the molecular mechanism, a global gene expression profile of BCL11B -siRNA -treated Molt-4 cells was established. The expression profiles of several genes were further validated in the BCL11B -siRNA -treated Molt-4 cells and primary T-ALL cells. Results 142 genes were found to be upregulated and 109 genes downregulated in the BCL11B -siRNA -treated Molt-4 cells by microarray analysis. Among apoptosis-related genes, three pro-apoptotic genes, TNFSF 10, BIK , BNIP 3, were upregulated and one anti-apoptotic gene, BCL2L 1 was downregulated. Moreover, the expression of SPP 1 and CREBBP genes involved in the transforming growth factor (TGF-β) pathway was down 16-fold. Expression levels of TNFSF 10, BCL2L 1, SPP 1, and CREBBP were also examined by real-time PCR. A similar expression pattern of TNFSF 10, BCL2L 1, and SPP 1 was identified. However, CREBBP was not downregulated in the BLC11B -siRNA -treated Molt-4 cells. Conclusion BCL11B -siRNA treatment altered expression profiles of TNFSF 10, BCL2L 1, and SPP 1 in both Molt-4 T cell line and primary T-ALL cells.
What problem does this paper attempt to address?